SCHEMBL3110165

SCHEMBL3110165

Cc1ccc(S(=O)(=O)N2CCCNCCCN(S(=O)(=O)c3ccc(C)cc3)Cc3cccc(c3)C2)cc1

nearest known ligand 0.54

Predicted protein targets (top 15)

geneUniProtsupporting neighboursconfidence
PKM P14618 5/20 0.54
ALDH1A1 P00352 4/20 0.54
HTT P42858 2/20 0.54
POLB P06746 1/20 0.54
LMNA P02545 3/20 0.50
SMN1; SMN2 Q16637 2/20 0.49
KMT2A Q03164 2/20 0.49
MEN1 O00255 1/20 0.49
GAA P10253 1/20 0.47
CD4 P01730 4/20 0.46
SORT1 Q99523 1/20 0.46
HSD11B1 P28845 1/20 0.45
HSD17B10 Q99714 1/20 0.45
TSHR P16473 1/20 0.44
NPSR1 Q6W5P4 1/20 0.44

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL23217199 0.84 PKM (0.74) PKMALDH1A1HTTPOLBLMNA
SCHEMBL3107328 0.83 CD4 (0.60) PKMALDH1A1HTTPOLBLMNA
Bromide SCHEMBL1159786 0.83 PKM (0.72) PKMALDH1A1HTTPOLBLMNA
SCHEMBL4109280 0.82 CD4 (0.60) PKMALDH1A1HTTPOLBLMNA
SCHEMBL1956663 0.82 ALDH1A1 (0.70) PKMALDH1A1HTTPOLBLMNA
SCHEMBL3111901 0.79 ALDH1A1 (0.76) PKMALDH1A1HTTPOLBLMNA
Aziridine SCHEMBL22778235 0.78 KMT2A (0.76) PKMALDH1A1HTTPOLBLMNA
SCHEMBL1259378 0.78 PKM (0.69) PKMALDH1A1HTTPOLBLMNA
SCHEMBL3976265 0.77 PKM (0.69) PKMALDH1A1HTTPOLBLMNA
SCHEMBL21361467 0.75 CD4 (0.53) PKMALDH1A1HTTPOLBLMNA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2163553-B1 ARENE CONNECTED POLYAMINE MACRORING DERIVATIVES, PREPARATION METHODS AND PHARMACEUTICAL USES THEREOF BEIJING MOLECULE SCIENCE AND TECHNOLOGY CO LTD (CN) 2013-12-25 EP disclosed
US-8420626-B2 Arene connected polyamine macrocyclic derivatives, preparation methods and pharmaceutical uses thereof BEIJING MOLECULE SCIENCE AND TECHNOLOGY CO., LTD. (CN) 2013-04-16 US disclosed
US-20100179116-A1 Arene Connected Polyamine Macrocyclic Derivatives, Preparation Methods and Pharmaceutical Uses Thereof BEIJING MOLECULE SCIENCE AND TECHNOLOGY CO., LTD. (CN) 2010-07-15 US disclosed
EP-2163553-A1 ARENE CONNECTED POLYAMINE MACRORING DERIVATIVES, PREPARATION METHODS AND PHARMACEUTICAL USES THEREOF Beijing Molecule Science and Technology Co., Ltd. (CN) 2010-03-17 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100179116-A1 Arene Connected Polyamine Macrocyclic Derivatives, Preparation Methods and Pharmaceutical Uses Thereof SRM, SP1, SMS PKM 119/4885ALDH1A1 1826/4885HTT 578/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.